7 April 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of alpelisib in the NHS in England. The appraisal committee has considered the evidence submitted by Novartis and the views of non-company consultees and commentators, clinical experts and patient experts.

Alpelisib, when use in combination with fulvestrant is not recommended, within its marketing authorisation, for the treatment of men or post-menopausal women with hormone receptor positive, HER2 negative, PIK3CA mutated, locally advanced or metastatic breast cancer who have disease progression after endocrine based therapy.

Read NICE appraisal consultation document